What's Happening?
DiaMedica Therapeutics has made significant progress in developing KLK1 therapeutics, focusing on ischemic stroke and preeclampsia. The company has overcome manufacturing challenges by engineering KLK1 with specific glycosylation patterns, partnering
with Catalent for production. Their lead compound, DM199, is in Phase II/III trials for acute ischemic stroke and is also being tested for preeclampsia. DM199 aims to restore KLK1 levels, enhancing blood flow and reducing blood pressure without crossing the placental barrier, making it a promising candidate for treating preeclampsia.
Why It's Important?
The development of KLK1 therapeutics by DiaMedica could address significant unmet medical needs in stroke and preeclampsia treatment. Current treatments for ischemic stroke are limited by narrow therapeutic windows, and there are no approved treatments for preeclampsia. DM199's ability to enhance blood circulation and its safety profile make it a potential breakthrough in these areas. Successful development could improve patient outcomes, reduce long-term disabilities, and provide a new treatment option for conditions with limited therapeutic options.
What's Next?
DiaMedica is focused on advancing its clinical trials, with multiple readouts expected by 2027. The company plans to initiate a Phase II study for early-onset preeclampsia and is conducting an interim analysis of its stroke trial. If successful, DM199 could become the first approved treatment for preeclampsia, offering the potential to extend gestational days and address the root cause of the disease. Continued progress in these trials will be crucial for regulatory approval and commercialization.
